J&J Brings In Multiple Sclerosis Candidate Via Licensing Pact With Pipeline
Deal Snapshot: Pipeline gets $50m up front and a $25m equity investment in exchange for global rights to an M1 receptor antagonist cleared to move into Phase II in relapsing/remitting MS.
You may also be interested in...
Eli Lilly, striving to outpace Novo Nordisk, dominated the dealmaking scene in 2023 by executing six acquisitions. Although Pfizer, BMS and AbbVie sealed the largest M&A deals of the year, they did not lead in terms of volume.
Shin Nippon Biomedical Laboratories would take over migraine candidate STS101, now under FDA review. Blue Water Vaccines to pick up BPH drug from Veru.
Ponesimod is the fourth S1P modulator approved to treat multiple sclerosis and joins a sprawling class of oral and injectable therapies. But Janssen sees numerous ways to differentiate its drug.